Theravance-GSK's COPD drug wins support of FDA panel

04/18/2013 | Reuters · Bloomberg Businessweek

A panel of FDA advisers endorsed the approval of GlaxoSmithKline and Theravance's Breo Ellipta as a treatment for chronic obstructive pulmonary disease. The once-daily inhaled treatment, a combination of fluticasone furoate and vilanterol, would compete with GSK's Advair and AstraZeneca's Symbicort. The FDA could issue a decision by May 12.

View Full Article in:

Reuters · Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA